<p>, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO)（&#34;Dario&#34;或&#34;公司&#34;），全球數字健康市場的領導者，今天宣佈進行一項私人配售，出售 2,713,180 股普通股（或相應的普通股等價物），每股價格為 6.45 美元，預計總收益約為 1750 萬美元，未扣除發行費用。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="400" height="351" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg"/></p>
<p>此次發行的交割預計將在 2025 年 9 月 23 日左右進行，具體取決於常規交割條件的滿足。公司計劃將此次發行的淨收益用於一般企業用途。</p>
<p>此次發行是基於《1933 年證券法》第 4(a)(2) 條款的註冊要求豁免進行的（經修訂的&#34;證券法&#34;），和/或根據其下發布的 D 條款，以及適用的州證券法。因此，私人配售中提供的證券不得在美國提供或出售，除非根據有效的註冊聲明或適用的註冊要求豁免。公司已同意向證券交易委員會（&#34;SEC&#34;）提交註冊聲明，註冊私人配售中出售的普通股的轉售。</p>
<p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他司法管轄區進行這些證券的出售，除非在任何此類州或其他司法管轄區的證券法下注冊或資格之前進行的要約、邀請或出售是合法的。</p>
<p><strong>關於 DarioHealth Corp.</strong></p>
<p>DarioHealth Corp.（NASDAQ: DRIO）是一家領先的數字健康公司，通過以用户為中心的多慢性病數字治療平台，徹底改變慢性病患者管理健康的方式。我們的平台和解決方案組合提供個性化和動態的干預措施，基於數據分析和一對一的指導，涵蓋糖尿病、高血壓、體重管理、肌肉骨骼疼痛和行為健康。</p>
<p>我們的以用户為中心的平台為人們提供持續和定製的健康護理，顛覆了傳統的偶發醫療保健方式。這種方法使人們能夠全面調整他們的生活方式，以實現可持續的行為改變，從而推動卓越的用户滿意度、留存率和結果，使正確的選擇變得容易。</p>
<p>Dario 在全球範圍內向健康計劃和其他支付方、自保僱主、護理提供者和消費者提供其高度用户評價的解決方案。要了解更多關於 Dario 及其數字健康解決方案的信息，請訪問 http://dariohealth.com。</p>
<p><strong>關於前瞻性聲明的警示説明</strong> 本新聞稿及公司代表和合作夥伴相關的聲明包含或可能包含 1995 年《私人證券訴訟改革法》意義上的前瞻性聲明。非歷史事實的聲明可能被視為前瞻性聲明。在不限制前述一般性的情況下，諸如&#34;計劃&#34;、&#34;項目&#34;、&#34;潛在&#34;、&#34;尋求&#34;、&#34;可能&#34;、&#34;將&#34;、&#34;期望&#34;、&#34;相信&#34;、&#34;預期&#34;、&#34;打算&#34;、&#34;可以&#34;、&#34;估計&#34;或&#34;繼續&#34;等詞語旨在識別前瞻性聲明。例如，公司在討論預計收益和發行交割的時間及收益的預期用途時使用了前瞻性聲明。讀者應注意，某些重要因素可能會影響公司的實際結果，並可能導致這些結果與本新聞稿中可能作出的任何前瞻性聲明有實質性差異。可能影響公司結果的因素包括但不限於監管批准、產品需求、市場接受度、競爭產品和價格的影響、產品開發、商業化或技術困難、談判和貿易的成功或失敗、法律、社會和經濟風險，以及與現有現金資源充足性相關的風險。其他可能導致公司實際結果與前瞻性聲明之間差異的因素包括但不限於公司在 SEC 的備案中討論的那些風險。讀者應注意，實際結果（包括但不限於公司對 Dario™的商業和監管計劃的時間和結果的描述）可能與前瞻性聲明中所述的結果有顯著差異。公司沒有義務公開更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，除非適用法律要求。</p>
<p><strong>DarioHealth 公司聯繫方式：</strong></p>
<p>DarioHealth 投資者關係聯繫人</p>
<p>Michael Lipari</p>
<p>企業發展高級副總裁</p>
<p>irteam@dariohealth.com</p>
<p>+1-201-785-6310</p>
<p>Zoe Harrison</p>
<p>會計與企業發展副總裁</p>
<p>irteam@dariohealth.com</p>
<p>+1-917-856-5505</p>
<p>Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg</p>
<p>來源 DarioHealth Corp.</p>

IMPP

DRIO

<p>DarioHealth Corp. 宣佈進行私募配售，出售 2,713,180 股普通股，價格為每股 6.45 美元，目標籌集約 1,750 萬美元。預計交易將在 2025 年 9 月 23 日左右完成，需滿足慣例條件。籌集的資金將用於一般企業用途。該發行在證券法下免於註冊，並將向 SEC 提交註冊聲明以供轉售。DarioHealth 是一家專注於慢性病管理的數字健康公司</p>

<p>, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (&#34;Dario&#34; or the &#34;Company&#34;), a leader in the global digital health market, today announced a private placement for the purchase and sale of 2,713,180 shares of common stock (or common stock equivalents in lieu thereof) at a price of $6.45 per share for expected aggregate gross proceeds of approximately $17.5 million, before deducting offering expenses.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO)（&#34;Dario&#34;或&#34;公司&#34;），全球數字健康市場的領導者，今天宣佈進行一項私人配售，出售 2,713,180 股普通股（或相應的普通股等價物），每股價格為 6.45 美元，預計總收益約為 1750 萬美元，未扣除發行費用。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg"/></p>
<p>The closing of the offering is expected to occur on or about September 23, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for general corporate purposes.</p>
<div class="lb-trans"><p>此次發行的交割預計將在 2025 年 9 月 23 日左右進行，具體取決於常規交割條件的滿足。公司計劃將此次發行的淨收益用於一般企業用途。</p>
</div><p>The offering is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and/or Regulation D promulgated thereunder, and applicable state securities laws. Accordingly, the securities offered in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirement of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission (the &#34;SEC&#34;) registering the resale of the shares of common stock sold in the private placement.</p>
<div class="lb-trans"><p>此次發行是基於《1933 年證券法》第 4(a)(2) 條款的註冊要求豁免進行的（經修訂的&#34;證券法&#34;），和/或根據其下發布的 D 條款，以及適用的州證券法。因此，私人配售中提供的證券不得在美國提供或出售，除非根據有效的註冊聲明或適用的註冊要求豁免。公司已同意向證券交易委員會（&#34;SEC&#34;）提交註冊聲明，註冊私人配售中出售的普通股的轉售。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他司法管轄區進行這些證券的出售，除非在任何此類州或其他司法管轄區的證券法下注冊或資格之前進行的要約、邀請或出售是合法的。</p>
</div><p><strong>About DarioHealth Corp.</strong></p>
<div class="lb-trans"><p><strong>關於 DarioHealth Corp.</strong></p>
</div><p>DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.</p>
<div class="lb-trans"><p>DarioHealth Corp.（NASDAQ: DRIO）是一家領先的數字健康公司，通過以用户為中心的多慢性病數字治療平台，徹底改變慢性病患者管理健康的方式。我們的平台和解決方案組合提供個性化和動態的干預措施，基於數據分析和一對一的指導，涵蓋糖尿病、高血壓、體重管理、肌肉骨骼疼痛和行為健康。</p>
</div><p>Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.</p>
<div class="lb-trans"><p>我們的以用户為中心的平台為人們提供持續和定製的健康護理，顛覆了傳統的偶發醫療保健方式。這種方法使人們能夠全面調整他們的生活方式，以實現可持續的行為改變，從而推動卓越的用户滿意度、留存率和結果，使正確的選擇變得容易。</p>
</div><p>Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.</p>
<div class="lb-trans"><p>Dario 在全球範圍內向健康計劃和其他支付方、自保僱主、護理提供者和消費者提供其高度用户評價的解決方案。要了解更多關於 Dario 及其數字健康解決方案的信息，請訪問 http://dariohealth.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong> This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#34;plan,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;seek,&#34; &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;could,&#34; &#34;estimate&#34; or &#34;continue&#34; are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected proceeds and timing of the closing of the offering and the intended use of proceeds. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the SEC. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong> 本新聞稿及公司代表和合作夥伴相關的聲明包含或可能包含 1995 年《私人證券訴訟改革法》意義上的前瞻性聲明。非歷史事實的聲明可能被視為前瞻性聲明。在不限制前述一般性的情況下，諸如&#34;計劃&#34;、&#34;項目&#34;、&#34;潛在&#34;、&#34;尋求&#34;、&#34;可能&#34;、&#34;將&#34;、&#34;期望&#34;、&#34;相信&#34;、&#34;預期&#34;、&#34;打算&#34;、&#34;可以&#34;、&#34;估計&#34;或&#34;繼續&#34;等詞語旨在識別前瞻性聲明。例如，公司在討論預計收益和發行交割的時間及收益的預期用途時使用了前瞻性聲明。讀者應注意，某些重要因素可能會影響公司的實際結果，並可能導致這些結果與本新聞稿中可能作出的任何前瞻性聲明有實質性差異。可能影響公司結果的因素包括但不限於監管批准、產品需求、市場接受度、競爭產品和價格的影響、產品開發、商業化或技術困難、談判和貿易的成功或失敗、法律、社會和經濟風險，以及與現有現金資源充足性相關的風險。其他可能導致公司實際結果與前瞻性聲明之間差異的因素包括但不限於公司在 SEC 的備案中討論的那些風險。讀者應注意，實際結果（包括但不限於公司對 Dario™的商業和監管計劃的時間和結果的描述）可能與前瞻性聲明中所述的結果有顯著差異。公司沒有義務公開更新任何前瞻性聲明，無論是由於新信息、未來事件還是其他原因，除非適用法律要求。</p>
</div><p><strong>DarioHealth Corporate Contacts:</strong></p>
<div class="lb-trans"><p><strong>DarioHealth 公司聯繫方式：</strong></p>
</div><p>DarioHealth Investor Relations Contact</p>
<div class="lb-trans"><p>DarioHealth 投資者關係聯繫人</p>
</div><p>Michael Lipari</p>
<div class="lb-trans"><p>Michael Lipari</p>
</div><p>SVP Corporate Development</p>
<div class="lb-trans"><p>企業發展高級副總裁</p>
</div><p>irteam@dariohealth.com</p>
<div class="lb-trans"><p>irteam@dariohealth.com</p>
</div><p>+1-201-785-6310</p>
<div class="lb-trans"><p>+1-201-785-6310</p>
</div><p>Zoe Harrison</p>
<div class="lb-trans"><p>Zoe Harrison</p>
</div><p>VP, Accounting and Corporate Development</p>
<div class="lb-trans"><p>會計與企業發展副總裁</p>
</div><p>irteam@dariohealth.com</p>
<div class="lb-trans"><p>irteam@dariohealth.com</p>
</div><p>+1-917-856-5505</p>
<div class="lb-trans"><p>+1-917-856-5505</p>
</div><p>Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg</p>
<div class="lb-trans"><p>Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg</p>
</div><p>SOURCE DarioHealth Corp.</p>
<div class="lb-trans"><p>來源 DarioHealth Corp.</p>
</div>

Imperial Petroleum Inc. 宣佈對 A 系列優先股派發股息 | IMPP 股票新聞